Boundless Bio, Inc. BOLD 深 沪
已收盘 10-17 16:00:00 美东时间
1.37
-0.040
-2.84%
华盛通- 最 高1.42
- 今 开1.40
- 成交量 12.91万股
- 最 低 1.35
- 昨 收 1.41
- 总市值 3066.83万
- 52周最高 3.75
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 1.00
- 委 比 73.02%
- 总股本 2238.56万
- 历史最高 15.24
- 量 比 0.52
- 振 幅 4.96%
- 历史最低 1.00
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Boundless Bio To Present Preclinical Data On BBI-825 And BBI-355 Combo Targeting Oncogene-Amplified Cancers At AACR-NCI-EORTC 2025
Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
10-14 04:10
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, will present a poster at the AACR-NCI-EORTC conference in Boston from October 22-26, 2025. The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355, targeting oncogene amplified cancers. BBI-825 is a selective RNR inhibitor, while BBI-355 is a selective CHK1 inhibitor. Both compounds are being evaluated in the phase 1/2 POTENTIATE trial. Boundless Bio s...
10-13 20:05
Paramount Marks Star Trek's 60th Anniversary With Rose Parade Debut, Starfleet Academy Series, Cruise Experience
Paramount Skydance is celebrating Star Trek's 60th anniversary in 2026 with a yearlong lineup that includes new shows, a Rose Parade float.
09-10 18:09
Henry Schein Authorizes $750M Share Repurchase Plan
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the
09-10 05:13
CHEEZ-IT® REINVENTS SNACKING WITH ALL-NEW CHEEZ-IT CRUNCH: DELIVERING MAX CRUNCH AND BOLD FLAVOR LIKE NEVER BEFORE
The brand's biggest innovation in three years is perfectly designed to deliver a flavor-forward, crunchy snacking experience Key News Bites Cheez-It® debuts new Cheez-It Crunch lineup combin...
09-08 20:00
BLOOMINGDALE'S UNVEILS BOLD FALL 2025 CAMPAIGN: JUST IMAGINE
An immersive celebration of art, identity, and modern retail arrives this fall at Bloomingdale's 59th Street flagship—featuring a striking façade and Carousel takeover, designed by acclaimed...
09-04 21:00
Praxis Precision Medicines To Present 12 Epilepsy Pipeline Updates, Including RADIANT Results, At IEC 2025 In Lisbon
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming
08-26 04:02
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
08-11 18:43
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
08-05 11:00
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
08-05 01:38
